Hydromoor™ - Moorfields` FIRST brand offers FIRST line defence
Moorfields Pharmaceuticals is hoping to create a few ripples in the dry eyes treatment sector, with the launch of its first branded artificial tear, Hydromoor™, a 0.3% hypromellose in a preservative-free unit dose.
Widely recognised as the number one first line treatment for the relief of symptoms of mild to moderate dry eye syndrome, Hydromoor™ 0.3% hypromellose will provide a cost competitive option bearing the name of one of the world’s most respected ophthalmic hospitals – Moorfields.
Hydromoor™ is also preservative-free, making it particularly suitable for rigid contact lens wearers, as well as those with sensitivity to preservatives in eye drops. As well as being the first line solution, it can also be used in conjunction with other treatments for patients with moderate symptoms of dry eyes.
In recent years, Moorfields Pharmaceuticals has developed a strong customer base for its hypromellose single unit dose eye drops. The move to the Hydromoor™ branded version reflects the growing importance of the product and a new direction for the company to establish itself as a pharmaceutical manufacturer within the ophthalmic sector.
Moorfields Pharmaceuticals has identified dry eye syndrome as a significant area of need and opportunity. It is a condition that increases with age with the over 60s most likely to suffer, but it is also influenced by lifestyle and environmental factors. Mild cases often go untreated but symptoms can often be relieved with preservative-free artificial tears, such as Hydromoor™, and lifestyle changes.
The company plans to focus on dry eye syndrome and launch a continuum of ocular lubricants and other therapies over the next 12 to 24 months.
Hydromoor™ carries a CE product mark and is classified as a medical device in the UK. The product can be ordered through pharmaceutical wholesalers.
For more information about Dry Eye Syndrome visit www.dryeyesmedical.com. The new health and medical professionals resource for the diagnosis and treatment of Dry Eye Syndrome.
Hydromoor is a trademark of Moorfields Pharmaceuticals Ltd.
November 2009
PR CONTACT: Lyn Wallace or kate Jones on +44 (0)20 8995 5354 or lyn@wallacehcl.com
EDITOR`S NOTES
Moorfields Pharmaceuticals is the pharmaceutical manufacturing facility of Moorfields Eye Hospital, one of the world’s leading ophthalmic hospitals providing expertise in clinical care, research and education.
Moorfields has prepared pharmaceutical products in response to clinical needs for over 50 years but in the 1990s it was identified as a revenue generating opportunity for the hospital.
In 2003 a purpose-built manufacturing facility was opened on a separate site next to Moorfields Eye Hospital.
MHRA licenses were awarded in 2004.
Moorfields Eye Hospital was awarded Foundation Trust status in April 2004 and Moorfields Pharmaceuticals was established as an autonomous business unit.
